1-methyl-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 1-methyl-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
• 英文别名: 1-Methyl-6-(morpholin-4-ylmethyl)-4-oxoquinoline-3-carboxylic acid
• 化学式: C₁₆H₁₈N₂O₄
• 分子量: 302.33
• InChiKey: XLOIHBHFDPPKJF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  70.1
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT
  申请人：Japan Tobacco Inc.

  公开号：US20150174117A1

  公开（公告）日：2015-06-25

  An anti-HIV agent containing, as an active ingredient, a 4-oxoquinoline compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. The compound of the present invention has HIV integrase inhibitory action and is useful as an anti-HIV agent for the prophylaxis or therapy of AIDS. Moreover, by a combined use with other anti-HIV agents such as protease inhibitors, reverse transcriptase inhibitors and the like, the compound can become a more effective anti-HIV agent. Since the compound has high inhibitory activity specific for integrases, it can provide a safe pharmaceutical agent with a fewer side effects for human.

  一种抗HIV剂，其活性成分为以下式[I]所代表的4-氧喹啉化合物，其中每个符号在规范中定义，或其药学上可接受的盐。本发明的化合物具有HIV整合酶抑制作用，并且可用作预防或治疗艾滋病的抗HIV剂。此外，通过与其他抗HIV剂（如蛋白酶抑制剂，逆转录酶抑制剂等）的联合使用，该化合物可以成为更有效的抗HIV剂。由于该化合物具有高度特异性的整合酶抑制活性，因此可以提供一种对人体副作用较少的安全药物。
• 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS HIV INTEGRASE INHIBITOR
  申请人：SATOH Motohide

  公开号：US20130172344A1

  公开（公告）日：2013-07-04

  An anti-HIV agent containing, as an active ingredient, a 4-oxoquinoline compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. The compound of the present invention has HIV integrase inhibitory action and is useful as an anti-HIV agent for the prophylaxis or therapy of AIDS. Moreover, by a combined use with other anti-HIV agents such as protease inhibitors, reverse transcriptase inhibitors and the like, the compound can become a more effective anti-HIV agent. Since the compound has high inhibitory activity specific for integrases, it can provide a safe pharmaceutical agent with a fewer side effects for human.

  一种抗HIV药剂，其含有以下式[I]所表示的4-氧喹啉化合物作为活性成分，其中每个符号如规范中所定义，或其药学上可接受的盐。本发明的化合物具有HIV整合酶抑制作用，可用于预防或治疗艾滋病的抗HIV药剂。此外，与其他抗HIV药剂（如蛋白酶抑制剂、反转录酶抑制剂等）联合使用，该化合物可以成为更有效的抗HIV药剂。由于该化合物具有针对整合酶的高抑制活性，因此可以提供一种对人体副作用更少的安全药物。
• [EN] 4-OXO-1,4-DIHYDRO-3-QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS<br/>[FR] AGENTS ANTIVIRAUX DE 4-OXO-1,4-DIHYDRO-3-QUINOLINECARBOXAMIDES,
  申请人：UPJOHN CO

  公开号：WO2000040563A1

  公开（公告）日：2000-07-13

  The present invention provides a compound of formula (I) Wherein R1 is C¿1-7? alkyl, optionally substituted by hydroxy or NR?4R5; R2¿ is C¿1-7? alkyl substituted by hydroxy or NR?4R5; R3¿ is H, F or C¿1-7? alkoxy; R?4 and R5¿ together with N are a 5- or 6-membered heterocyclic moiety having 1-3 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur in which sulfur may be substituted by one (1) or two (2) oxygen atoms; and pharmaceutically acceptable salts thereof. Compounds of formula (I) of the present invention are useful as antiviral agents.

  本发明提供了一种化合物，其化学式为（I），其中R1是C1-7烷基，可选择性地取代为羟基或NR4R5；R2是C1-7烷基，取代为羟基或NR4R5；R3是H，F或C1-7烷氧基；R4和R5与N一起形成一个5-或6-成员杂环基团，其中包括1-3个异原子，所述异原子选择自氮、氧和硫的群组，其中硫可以被一个（1）或两个（2）氧原子取代；以及其药学上可接受的盐。本发明的化合物（I）可用作抗病毒剂。
• Combination Therapy
  申请人：JAPAN TOBACCO INC.

  公开号：US20140364389A1

  公开（公告）日：2014-12-11

  The present invention relates to a combination therapy for treating an HIV infection or inhibiting integrase comprising (S)-6-(3-Chloro-2-fluorobenzyl)-1-(1-hydroxymethyl-2-methylpropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (“Compound A”) or a pharmaceutically acceptable solvate or salt thereof in combination with at least one other anti-HIV agent. In some embodiments of the present invention, the other anti-HIV agents are chosen from reverse transcriptase inhibitors and protease inhibitors. In certain embodiments of the present invention, the other anti-HIV agents are chosen from AZT, 3TC, PMPA, efavirenz, indinavir, nelfinavir, a combination of AZT/3TC, and a combination of PMPA/3TC. Since Compound A has a high inhibitory activity specific for integrases, when used in combinations with other anti-HIV agents it can provide a combination therapy with fewer side effects for humans.

  本发明涉及一种联合治疗HIV感染或抑制整合酶的组合疗法，包括（S）-6-（3-氯-2-氟苯基）-1-（1-羟甲基-2-甲基丙基）-7-甲氧基-4-氧代-1，4-二氢喹啉-3-羧酸（“化合物A”）或其药学上可接受的溶剂化物或盐与至少一种其他抗HIV剂的联合使用。在本发明的某些实施例中，其他抗HIV药物选择自反转录酶抑制剂和蛋白酶抑制剂。在本发明的某些实施例中，其他抗HIV剂选择自AZT，3TC，PMPA，依法韦伦，印地那韦，奈非那韦，AZT / 3TC的组合和PMPA / 3TC的组合。由于化合物A具有高特异性抑制整合酶的活性，当与其他抗HIV药物联合使用时，可以为人类提供更少的副作用的联合治疗。
• 4-OXO-1,4-DIHYDRO-3-QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS
  申请人：PHARMACIA & UPJOHN COMPANY

  公开号：EP1140851A1

  公开（公告）日：2001-10-10